@dansfera: The crucial question for any clinical site owner looking to sell: What are buyers *actually* scrutinizing during due diligence? It's a deep dive into concentration risk across the board! Think sponsors—are you too reliant on just a few? What about therapeutic area diversity? Savvy buyers trace every PI and Sub-I relationship, needing to see that studies aren't bottlenecked through a single source. Unpacking these concentration hotspots is the key to understanding your true valuation. Essential knowledge for that big exit! 💡 #ClinicalResearch #MNA #DueDiligence #BiotechInvesting #SiteOwner